Clinical Trials on Respiratory Syncytial Virus in United Kingdom

Total 26092 results

National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

Respiratory Syncytial Virus Infections

United States
MedImmune LLC

Completed

Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults

Respiratory Syncytial Virus Infections

United States
Abbott

Completed

Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease

Severe Respiratory Syncytial Virus Infection

Austria, Belgium, France, Germany, Italy, Norway, Poland, Slovenia, Spain, United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children

Respiratory Syncytial Virus Infections

United States
Bavarian Nordic

Completed

Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine

Respiratory Syncytial Virus Infections

United States
West Penn Allegheny Health System
American Academy of Allergy, Asthma, and Immunology

Completed

Association Between Cytokines and Severity of Respiratory Syncytial Virus (RSV)-Induced Illness in the Elderly

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

Respiratory Syncytial Virus Infections

United States
Novavax

Completed

Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...
Johns Hopkins Bloomberg School of Public Health

Active, not recruiting

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
Pfizer

Completed

A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants

Respiratory Syncytial Virus Infections

United States
Meissa Vaccines, Inc.

Completed

Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children

Respiratory Syncytial Virus Infections

United States
Alnylam Pharmaceuticals

Completed

Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults

Respiratory Syncytial Virus Infections

United States
MedImmune LLC

Completed

A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants (MEDI8897 1b)

Respiratory Syncytial Virus

United States, South Africa, Chile
GlaxoSmithKline

Withdrawn

A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy

Respiratory Syncytial Virus Infections

United States
M.D. Anderson Cancer Center

Completed

Respiratory Syncytial Virus - RSV Protocol

Cancer | Acute Leukemia | Respiratory Syncytial Virus Infections | Bone Marrow Transplant Infection | Infection in Marrow Transplant Recipients | Respiratory Syncytial Virus Pneumonia

United States
Meissa Vaccines, Inc.

Completed

Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children

Respiratory Syncytial Virus Infections

United States
UMC Utrecht
University of Turku; University of Oxford; University of Edinburgh; Servizo Galego...

Active, not recruiting

RESCEU Study: Defining the Burden of Disease of Respiratory Syncytial Virus in Europe in Infants

Respiratory Syncytial Virus Infections | RSV Infection | RSV Bronchiolitis

United Kingdom, Netherlands, Finland, Spain
Janssen Sciences Ireland UC

Terminated

Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV) (FREESIA)

Respiratory Syncytial Virus Infections

United States, Belgium, Taiwan, Israel, Japan, Argentina, Malaysia, Korea, Republic of, Netherlands, Spain, Australia, Italy, Brazil, France, United Kingdom, Sweden, Bulgaria
National Institute of Allergy and Infectious Diseases...

Terminated

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age (LID)

Respiratory Syncytial Virus Infections

United States
Codagenix, Inc

Recruiting

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

Respiratory Syncytial Virus Infections

United States
Novavax

Completed

RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.

Respiratory Syncytial Virus Infections

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

RSV Infection

United States
Alios Biopharma Inc.

Completed

A Study of ALS-008176 in Infants Hospitalized With RSV

Respiratory Syncytial Virus Infections

United States, Taiwan, Australia, Canada, United Kingdom, Colombia, France, New Zealand, Japan, South Africa, Chile, Panama, Romania, Thailand
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children

RSV Infection

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

RSV Infection

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

RSV Infection

United States
Gilead Sciences

Completed

A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806

RSV Infection

United States
Pfizer

Completed

A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age (PICASSO)

RESPIRATORY SYNCYTIAL VIRUS (RSV)

United States
Yale University
National Institute of Allergy and Infectious Diseases (NIAID)

Not yet recruiting

Real-World Effectiveness of Perinatal RSV Immunoprophylaxis

RSV Infection

United States
Novavax
Bill and Melinda Gates Foundation

Completed

A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization

Respiratory Syncytial Virus Infections

United States, Argentina, Australia, Bangladesh, Chile, Mexico, New Zealand, Philippines, South Africa, Spain, United Kingdom
Blue Lake Biotechnology Inc.

Completed

Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults

Respiratory Syncytial Virus Infections

United States
GlaxoSmithKline

Completed

A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women

Respiratory Syncytial Virus Infections

United States, Germany, Finland
National Institute of Allergy and Infectious Diseases...

Recruiting

Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children

RSV Infection

United States
Bill & Melinda Gates Medical Research Institute
PPD Phase I Clinic - Orlando

Completed

Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults

RSV Infection

United States
Enanta Pharmaceuticals, Inc

Completed

A Study of EDP-323 in Healthy Subjects

RSV Infection

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-938 in Healthy Subjects

RSV Infection

United States
Enanta Pharmaceuticals, Inc

Completed

Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects

RSV Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
GlaxoSmithKline

Withdrawn

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

Respiratory Syncytial Virus Infections

Finland, United States, Spain
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
Bavarian Nordic

Completed

RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

Respiratory Syncytial Virus Infections

United States
Novavax

Completed

RSV F Dose-Ranging Study in Women

Respiratory Syncytial Virus Infections

United States

3

Subscribe